In calendar year 2025, 340B covered entities purchased $100 billion in covered outpatient drugs under the 340B Program. The information below details the aggregate 340B purchases by covered entity type in 2025.
| Entity Type | 2025 Total Purchases |
|---|---|
| Disproportionate Share Hospitals | $79,235,079,126 |
| Health Center Programs | $5,923,068,523 |
| Children's Hospitals | $2,530,112,366 |
| Rural Referral Centers | $2,450,316,245 |
| Ryan White HIV/AIDS Program Part A | $1,715,605,648 |
| Sexually Transmitted Disease Clinics | $2,860,922,521 |
| Critical Access Hospitals | $1,534,847,257 |
| Ryan White HIV/AIDS Program Part C | $852,864,925 |
| Sole Community Hospitals | $632,063,322 |
| Free-standing Cancer Centers | $741,495,526 |
| Ryan White HIV/AIDS Program Part B | $396,112,488 |
| Ryan White Part B AIDS Drug Assistance Program (ADAP) Direct Purchase Option | $95,687,979 |
| Comprehensive Hemophilia Treatment Centers | $328,719,206 |
| Federally Qualified Health Center Look-Alike Program | $517,582,250 |
| Family Planning Clinics | $28,867,175 |
| Ryan White HIV/AIDS Program Part D | $32,417,529 |
| Tribal Contract/Compact with IHS (P.L. 93-638) | $115,479,102 |
| Tuberculosis Clinics | $13,074,491 |
| Urban Indian Hospitals | $4,060,361 |
| Black Lung Clinics | $2,511,629 |
| Ryan White Part B ADAP Rebate Option | $835 |
| Native Hawaiian Heath Care Programs | $84,813 |
| Total | $100,010,973,317 |
Key data on 340B sales
- US payer net spending on prescription drugs in the U.S. grew 9.08% in 2025, for a total of $901 billion, and revenues received by manufacturers increased to $601 billion. 1
- Therapeutic areas that were primary drivers of growth included oncology, immunology, and obesity.1 Trends impacting the healthcare market nationally are also reflected in the 340B space.
- The 340B Program is limited to outpatient settings. The scope of ambulatory care has expanded in volume and complexity of interventions over the past decade.2 As care increasingly shifts from inpatient to outpatient settings, spending on drugs associated with outpatient care increases. For example, oncology drugs, biologics, and other infusion therapies administered in hospital outpatient departments represent the fastest-growing segment of purchases in the 340B Program. Other key drivers of growth in the 340B Program include an increase in drug utilization, the introduction of innovative therapies, and price increases.
- In alignment with the national trend, high-cost pharmaceuticals purchased through specialty distribution channels in the 340B Program represent an increasing proportion of the amount of 340B spending. While representing only 38.1% of all 340B units purchased, these high-cost pharmaceuticals purchased in the 340B Program through specialty channels accounted for 61.9% ($61.9 billion) of reported 340B purchases – illustrating the significant impact that the relatively smaller numbers of specialty units purchased has on overall 340B purchases.
- In 2025, the top 10 drugs in terms of 340B purchases represented approximately 28.6% of the total spending in the 340B Program.
| Brand Name | Primary Indication (s) | 2024 Total 340B Sales |
|---|---|---|
| Keytruda | Oncology | $8,890,434,757 |
| Biktarvy | HIV | $4,761,694,943 |
| Darzalex Faspro | Oncology | $3,123,756,468 |
| Opdivo | Oncology | $2,391,880,926 |
| Ocrevus | Multiple Sclerosis | $1,933,112,210 |
| Mounjaro | Diabetes; Weight Management | $1,754,738,648 |
| Imfinzi | Oncology | $1,491,915,656 |
| Descovy | HIV | $1,490,911,970 |
| Trikafta | Cystic Fibrosis | $1,485,487,104 |
| Vyndamax | Cardiology | $1,278,423,794 |
Note: These 340B purchase data are provided by the 340B Prime Vendor Program, which was established by the 340B statute. The Prime Vendor Program is managed through a contract with the Health Resources and Services Administration. The Prime Vendor Program captures the vast majority but not all 340B transactions. These figures are accurate as of June 30, 2026. The purchase data provided is a culmination of transactional data captured at a given point in time, as corrections and adjustments are made to invoices on an ongoing basis.
1 See: U.S. Medicine Use Trends 2026- IQVIA
2See: Ambulatory Care | Agency for Healthcare Research and Quality